enGenes and acib to prove efficient site-specific incorporation of non-canonical amino acids into proteins

Vienna, Austria: – Recombinant protein specialist manufacturer enGenes Biotech GmbH (enGenes) is undertaking a proof-of-concept project that applies its patented enGenes-eXpress technology to the cost-effective site-directed incorporation of non-canonical amino acids into proteins.

enGenes will be working as part of the XPAND project in partnership with the Austrian Centre of Industrial Biotechnology (acib). The project is funded by the Austrian Research Agency (FFG).

Antibody mimetic protein

Already, the partners have successfully achieved site-directed incorporation of non-natural azido-lysin into the model protein GFP and a Her2-directed affibody, an antibody mimetic protein.

The XPAND partners will reach out to companies interested in bio-conjugation to develop this technology further.

For more information follow https://www.pharmaceutical-networking.com/engenes-and-acib-to-prove-efficient-site-specific-incorporation-of-non-canonical-amino-acids-into-proteins/